Zobrazeno 1 - 10
of 308
pro vyhledávání: '"Jack, Mardekian"'
Autor:
Angela DeMichele, Massimo Cristofanilli, Adam Brufsky, Xianchen Liu, Jack Mardekian, Lynn McRoy, Rachel M. Layman, Birol Emir, Mylin A. Torres, Hope S. Rugo, Richard S. Finn
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-10 (2021)
Abstract Background Findings from randomized clinical trials may have limited generalizability to patients treated in routine clinical practice. This study examined the effectiveness of first-line palbociclib plus letrozole versus letrozole alone on
Externí odkaz:
https://doaj.org/article/ffd7b19aa36e4377b6f02a192829a6e4
Autor:
David M. Waterhouse, Janet L. Espirito, Marc D. Chioda, Bismark Baidoo, Jack Mardekian, Nicholas J. Robert, Elizabeth T. Masters
Publikováno v:
Drugs - Real World Outcomes, Vol 7, Iss 4, Pp 261-269 (2020)
Abstract Background Data are sparse concerning the sequential use of multiple anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Objective This study investigated sequencing
Externí odkaz:
https://doaj.org/article/03f7a6aab37f4777abb0d63f1f78689f
Autor:
Pedro Gabriel Melo de Barros e Silva, Henry Sznejder, Rafael Vasconcellos, Georgette M. Charles, Hugo Tannus F. Mendonca-Filho, Jack Mardekian, Rodrigo Nascimento, Stephen Dukacz, Manuela Di Fusco
Publikováno v:
Arquivos Brasileiros de Cardiologia, Vol 114, Iss 3, Pp 457-466 (2020)
Abstract Background: The safety and effectiveness of warfarin depend on anticoagulation control quality. Observational studies associate poor control with increased morbidity, mortality and healthcare costs. Objectives: To develop a profile of non-va
Externí odkaz:
https://doaj.org/article/42498726664d47f9a27f2a9070c1fc9e
Autor:
Peter L Elkin, Sarah Mullin, Jack Mardekian, Christopher Crowner, Sylvester Sakilay, Shyamashree Sinha, Gary Brady, Marcia Wright, Kimberly Nolen, JoAnn Trainer, Ross Koppel, Daniel Schlegel, Sashank Kaushik, Jane Zhao, Buer Song, Edwin Anand
Publikováno v:
Journal of Medical Internet Research, Vol 23, Iss 11, p e28946 (2021)
BackgroundNonvalvular atrial fibrillation (NVAF) affects almost 6 million Americans and is a major contributor to stroke but is significantly undiagnosed and undertreated despite explicit guidelines for oral anticoagulation. ObjectiveThe aim of this
Externí odkaz:
https://doaj.org/article/1a4ff3525b7e43418f934f3028012f6c
Autor:
Kiran Gupta, Jeffrey Trocio, Allison Keshishian, Qisu Zhang, Oluwaseyi Dina, Jack Mardekian, Anagha Nadkarni, Thomas C Shank
Publikováno v:
BMC Cardiovascular Disorders, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among patients with non-valvular atrial fibrillation (NVAF), but
Externí odkaz:
https://doaj.org/article/0e59f113745d43bf897ef028f78cd1f3
Autor:
Steven Deitelzweig, Allison Keshishian, Amiee Kang, Amol D. Dhamane, Xuemei Luo, Neeraja Balachander, Lisa Rosenblatt, Jack Mardekian, Jenny Jiang, Huseyin Yuce, Gregory Y. H. Lip
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Gastrointestinal (GI) bleeding is the most common type of major bleeding associated with oral anticoagulant (OAC) treatment. Patients with major bleeding are at an increased risk of a stroke if an OAC is not reinitiated. Methods: Non-valv
Externí odkaz:
https://doaj.org/article/88a1ea97d6ae4b2f853bcc67dcc2d0e1
Autor:
Haseeb Saeed MD, Oscar Garza Ovalle MD, Ujala Bokhary MBBS, Anastasia Jermihov BS, Kamila Lepkowska MHA, Victoria Bauer BS, Kristine Kuchta MS, Marcia Wright PharmD, Scott Glosner BS, PharmD, BCPS, MPH, Margaret Frazer MD, Andres Quintero MD, MPH, MBA, Patrick Hlavacek MPH, Jack Mardekian PhD, Alfonso Tafur MD, Mark Metzl MD, Jorge Saucedo MD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Introduction: NVAF is estimated to affect between 6.4 and 7.4 million Americans in 2018, and increases the risk of stroke 5-fold. To mitigate this risk, guidelines recommend anticoagulating AF patients unless their stroke risk is very low. Despite th
Externí odkaz:
https://doaj.org/article/2930a43ddf654bccaf3b68c11718c7ac
Publikováno v:
Open Heart, Vol 7, Iss 1 (2020)
ObjectiveTo assess the safety (ie, risk of bleeding) and effectiveness (ie, risk of stroke/systemic embolism (SE)) separately for four non-vitamin K oral anticoagulants (NOACs; apixaban, dabigatran, edoxaban and rivaroxaban) versus warfarin in Japane
Externí odkaz:
https://doaj.org/article/259bb22bd2aa4eeda86ea5db68aa0d9e
Autor:
Cynthia Huang Bartlett, Jack Mardekian, Matthew James Cotter, Xin Huang, Zhe Zhang, Christina M Parrinello, Ariel Bulua Bourla
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0227256 (2020)
There is growing interest in leveraging real-world data to complement knowledge gained from randomized clinical trials and inform the design of prospective randomized studies in oncology. The present study compared clinical outcomes in women with met
Externí odkaz:
https://doaj.org/article/4e74ebefa98140199420adc1c7d5e62e
Autor:
Christine L. Baker JD, MPH, Amol D. Dhamane BPharm, MS, Jigar Rajpura PhD, Jack Mardekian PhD, Oluwaseyi Dina MPH, Cristina Russ MD, PhD, Lisa Rosenblatt MD, MPH, Melissa Lingohr-Smith PhD, Jay Lin PhD, MBA
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 25 (2019)
We compared the risks of switching to another oral anticoagulant (OAC) and discontinuation of direct oral anticoagulants (DOACs) among elderly patients with nonvalvular atrial fibrillation (NVAF) who were prescribed rivaroxaban or dabigatran versus a
Externí odkaz:
https://doaj.org/article/e5cb559b02f84f8bba59c8e7e14665f3